BMY•benzinga•
Goldman Sachs Downgrades Bristol-Myers Squibb to Neutral, Lowers Price Target to $55
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 8, 2025 by benzinga